ARK Investment Management Holds 9.9% Stake in CRISPR Therapeutics

TL;DR

**ARK still owns a huge chunk of CRSP, showing strong conviction!**

AI Summary

ARK Investment Management LLC, led by Cathie Wood, filed an amended SC 13G/A on January 29, 2024, disclosing its ownership in CRISPR Therapeutics AG (CRSP) as of December 31, 2023. The filing shows ARK beneficially owns 8,536,104 shares of common stock, representing 9.9% of the company. This is a significant holding for ARK, indicating continued conviction in CRISPR's gene-editing technology, which could impact the stock's perception and trading volume for investors.

Why It Matters

This filing reveals ARK's substantial and continued investment in CRISPR Therapeutics, signaling their belief in the company's future, which can influence other investors' decisions and potentially stabilize or boost the stock price.

Risk Assessment

Risk Level: low — This filing indicates a stable, significant institutional holding, which generally reduces volatility and provides a vote of confidence in the company.

Analyst Insight

A smart investor would view this as a strong vote of confidence from a prominent institutional investor, potentially signaling a positive long-term outlook for CRISPR Therapeutics AG, and might consider further research into CRSP's fundamentals and ARK's investment thesis.

Key Numbers

• 8,536,104 — Aggregate Shares Beneficially Owned (This is the total number of CRISPR Therapeutics AG shares ARK Investment Management LLC holds.)
• 9.9% — Percentage of Class (This represents a significant portion of CRISPR Therapeutics AG's common stock held by ARK.)
• 8,057,147 — Sole Voting Power Shares (This indicates the number of shares ARK can vote independently.)
• 244,377 — Shared Voting Power Shares (This shows the number of shares ARK can vote in conjunction with others.)
• 8,536,104 — Sole Dispositive Power Shares (This is the number of shares ARK can sell or dispose of independently.)

Key Players & Entities

• ARK Investment Management LLC (company) — the reporting person filing the SC 13G/A
• CRISPR Therapeutics AG (company) — the subject company in which shares are held
• 8,536,104 (dollar_amount) — the aggregate number of shares beneficially owned by ARK
• 9.9% (dollar_amount) — the percentage of CRISPR Therapeutics AG's common stock owned by ARK
• December 31, 2023 (date) — the date of the event requiring the filing

Forward-Looking Statements

• ARK Investment Management LLC will maintain a significant stake in CRISPR Therapeutics AG throughout 2024, signaling continued confidence in gene-editing technology. (ARK Investment Management LLC) — high confidence, target: December 31, 2024

FAQ

Filing Documents

• tm244117d15_sc13ga.htm (SC 13G/A) — 44KB
• 0001104659-24-007685.txt ( ) — 46KB

(a) Name of issuer

Item 1(a) Name of issuer: CRISPR Therapeutics AG

(b) Address of issuer's principal executive offices

Item 1(b) Address of issuer's principal executive offices: Baarerstrasse 14 Zug V8 CH-6300

(a) Name of person filing

Item 2(a) Name of person filing: ARK Investment Management LLC

(b) Address or principal business office or, if none,

Item 2(b) Address or principal business office or, if none, residence: ARK Investment Management LLC 200 Central Avenue St. Petersburg, FL 33701

(c) Citizenship

Item 2(c) Citizenship: Delaware, United States

(d) Title of class of securities

Item 2(d) Title of class of securities: Common stock

(e) CUSIP No

Item 2(e) CUSIP No.: H17182108

If this statement is filed pursuant to §§ 240.13d-1(b) or

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8); (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ CUSIP No. H17182108 13G Page 4 of 5 Pages

Ownership

Item 4. Ownership (a) Amount beneficially owned: 8,536,104 (b) Percent of class: 10.75% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 8,057,147 (ii) Shared power to vote or to direct the vote: 244,377 (iii) Sole power to dispose or to direct the disposition of: 8,536,104 (iv) Shared power to dispose or to direct the disposition of: 0

Ownership of 5 Percent or Less of a Class

Item 5. Ownership of 5 Percent or Less of a Class. Not applicable.

Ownership of More than 5 Percent on Behalf of Another Person

Item 6. Ownership of More than 5 Percent on Behalf of Another Person. To the knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the shares which represents more than five percent of the number of outstanding class of the shares. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group. Not applicable.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group. Not applicable. CUSIP No. H17182108 13G Page 5 of 5 Pages

Certifications

Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. The reporting persons agree that this statement is filed on behalf of each of them. Dated: January 29, 2024 ARK Investment Management LLC By: /s/ Kellen Carter Name: Kellen Carter Title: Chief Compliance Officer

View Full Filing

View this SC 13G/A filing on SEC EDGAR